Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

22.6%

7 terminated/withdrawn out of 31 trials

Success Rate

63.2%

-23.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

58%

7 of 12 completed trials have results

Key Signals

7 recruiting7 with results5 withdrawn

Enrollment Performance

Analytics

Phase 2
13(46.4%)
Phase 1
12(42.9%)
N/A
3(10.7%)
28Total
Phase 2(13)
Phase 1(12)
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (31)

Showing 20 of 31 trials
NCT03410030Phase 1Completed

Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)

Role: collaborator

NCT03762590Not ApplicableActive Not Recruiting

GENetic Education Risk Assessment and TEsting Study

Role: collaborator

NCT07671339Phase 1Recruiting

A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

Role: collaborator

NCT07199764Phase 2Recruiting

Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer

Role: collaborator

NCT05419479Phase 1Suspended

Switch Maintenance in Pancreatic

Role: collaborator

NCT06252545Not ApplicableRecruiting

Promoting CT Engagement for Pancreatic Cancer With App

Role: collaborator

NCT03415854Phase 2Completed

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

Role: collaborator

NCT06941857Phase 2Recruiting

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Role: collaborator

NCT06015659Phase 2Active Not Recruiting

ZN-c3 + Gemcitabine in Pancreatic Cancer

Role: collaborator

NCT05014776Phase 2Completed

Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer

Role: collaborator

NCT05077800Phase 2Active Not Recruiting

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Role: collaborator

NCT02110498Completed

Early Detection of Pancreatic Cystic Neoplasms

Role: collaborator

NCT01202136Completed

The Clinical,Radiologic,Pathologic and Molecular Marker Characteristics of Pancreatic Cysts Study

Role: collaborator

NCT06782932Phase 1Recruiting

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Role: collaborator

NCT03563248Phase 2Active Not Recruiting

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Role: collaborator

NCT05132244Not ApplicableRecruiting

Monitoring and Managing Glucose Levels in People With Pancreatic Cancer

Role: collaborator

NCT06747845Phase 2Recruiting

Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy

Role: collaborator

NCT02754726Phase 2Completed

Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Role: collaborator

NCT03697564Phase 2Completed

Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer

Role: collaborator

NCT06707896Phase 1Withdrawn

TCR1020-CD8 T Cells in KRAS-mutated Cancers

Role: collaborator